Navigation Links
Refractory Hematological Malignances Treatment Opportunities Discussed in MP Advisors Report Published at MarketPublishers.com
Date:9/12/2013

London, UK (PRWEB) September 12, 2013

Recently, cancer treatment has witnessed considerable breakthroughs in terms of the development of innovative drug products. The success in clinical research in this therapeutic area and growth in investments are attributed to positive clinical data and regulatory approvals, expanding partnerships and mergers and acquisitions (M&A) activity.

Some companies that have already scored a success in the development of novel technology platforms and drugs to treat relapsed and refractory multiple myeloma (RRMM), are expected to follow a similar scenario to unfold in the treatment of recurrent/refractory MDS (RR-MDS, High-Risk MDS) and AML (relapsed/ refractory AML, R/R AML).

Insightful research report “Treating Refractory Hematological Malignancies – Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): Emerging Therapeutics” worked out by MP Advisors has been recently published by Market Publishers Ltd.

Report Details:

Title: Treating Refractory Hematological Malignancies – Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): Emerging Therapeutics
Published: August, 2013
Pages: 37
Price:    US$ 2,500.00
http://marketpublishers.com/report/company_reports/treating-refractory-hematological-malignancies-v-myelodysplastic-syndromes-mds-n-acute-myeloid-leukemia-aml-emerging-therapeutics.html

The report offers an insightful overview of the approved therapies for MDS and AML, discusses the unmet needs as well as limitations of the current standard of care (SOC) for relapsed and refractory patients. The study examines commercial opportunities in purchasing the therapy area, evaluates the competitive pressure in the sphere; makes up a comprehensive list of drugs (both early-stage and late-stage) in the clinic, and also uncovers data on their mechanism of action and companies developing them; besides profiling the leading companies. The report presents a review of the recent mergers and acquisitions in the area; covers products available for in-licensing; discusses the major trends and issues related to the therapeutic area.

Report Scope:

  •     Insightful overview of the disease and a detailed discussion of the unmet needs.
  •     Vital information on the drugs in pipeline including mechanism of action (MoA) and clinical stage of development.
  •     Review of the key milestones.
  •     Data on the launch timeline and commercial opportunity of late-stage pipeline (RR MDS and RR AML).
  •     Extensive overview of the mergers and acquisitions and licensing deals over the past five years.
  •     Evaluation of the in-licensing and/or mergers and acquisitions opportunity.
  •     Description of the competitive scenario and detailed profiles of companies, including their clinical drug data, milestones and valuation.

More insightful research reports by MP Advisors can be found at http://marketpublishers.com/members/mpadvisors/info.html.

About Us:

MarketPublishers.com is a multilingual hypermarket offering a rich collection of comprehensive studies on various markets, sectors, industries, companies, etc. We perform professional services aimed to equip our clients with high-quality research products and support critical decision-making.

Read the full story at http://www.prweb.com/releases/2013/9/prweb11117498.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Analysis of KRYSTEXXA phase III data demonstrates improved health-related quality of life and physical function in refractory chronic gout patients
2. Refractory Hematological Malignancies (MDS, AML) Market Emerging Therapeutics Analysis Available at ReportsnReports.com
3. Effects of alcohol on lymphoma, leukemia, and other types of hematological cancers
4. Scientist awarded $1 million grant to develop tools for hepatitis C treatment discovery
5. Clinical insight improves treatment with new lung cancer drug
6. Rapid Asthma Treatment in ER May Prevent Admission
7. Novel compound demonstrates anti-leukemic effect in zebrafish, shows promise for human treatment
8. Breast cancer patients suffer treatment-related side effects long after completing care
9. Mayo Clinic offers newly approved treatment for acid reflux disease
10. Mobile Stroke Units Might Trim Time to Treatment
11. Breast Cancer Treatment Side Effects May Last for Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... Albuquerque, NM (PRWEB) , ... December 06, 2016 ... ... awarded JumpStart Autism Center with an Award of Distinction, recognizing the organization as ... needs providers that excel in the areas of clinical quality, staff satisfaction and ...
(Date:12/6/2016)... ... December 06, 2016 , ... Experimentation involving human stem cells ... due to its potential for revolutionizing human disease treatment. There are multiple HSC ... stem cells (hiPSCs). , Both platforms have distinct advantages and disadvantages, but ...
(Date:12/6/2016)... , ... December 06, 2016 , ... ... one-stop portal for all the knowledge resources, including white papers, guides, handbooks, case ... more. , To access more than 9,000 documents, webinars and videos available ...
(Date:12/6/2016)... , ... December 06, 2016 , ... 'Tis the season ... daily routines. That means it's also the season when eating healthy, staying active, and ... diabetes) on schedule is harder to do. , "Shopping trips, parties and family ...
(Date:12/6/2016)... ... 06, 2016 , ... Specialty Technical Publishers (STP) and Specialty ... Consortium (IAPC) EHS audit protocol for Great Britain . Leading companies around ... EHS regulatory obligations and rapidly collect, share, archive, and export audit findings in ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... , December 5, 2016 According to a new report ... by Application - Global Opportunity Analysis and Industry Forecast, 2014 - 2022", the ... to reach $5,255 million by 2022, growing at a CAGR of 6.4% from ... than four-fifths share. Continue Reading ... ...
(Date:12/5/2016)... and PUNE, India , December 5, ... by Allied Market Research, titled, "Global Cancer Biomarkers Market - ... of cancer biomarkers market is projected to reach $15,737 million ... of 13.3% from 2016 to 2022. Omic technologies segment accounted ... and is expected to maintain its dominance during the forecast ...
(Date:12/5/2016)... Dec. 5, 2016   TrainerMD , the first HIPAA compliant ... new collaboration with Styku . Styku, a ... Kinect hardware to provide users world-class, real-time 3D body scanning and ... the means to see, hear and feel their health like never ... , , ...
Breaking Medicine Technology: